TactiCath SE
Device
Abbott Laboratories
Total Payments
$1.3M
Transactions
253
Doctors
18
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $31,097 | 9 | 3 |
| 2020 | $45,264 | 15 | 11 |
| 2019 | $1.3M | 220 | 4 |
| 2018 | $7,281 | 9 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 223 | 94.3% |
| Grant | $71,197 | 20 | 5.3% |
| Space rental or facility fees (teaching hospital only) | $3,500 | 1 | 0.3% |
| Consulting Fee | $1,664 | 3 | 0.1% |
| Food and Beverage | $596.65 | 6 | 0.0% |
Payments by Type
Research
$1.3M
223 transactions
General
$76,958
30 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Safety and Effectiveness of TactiCath Contact Force, Sensor Enabled (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation (PERSIST-END Trial) | Abbott Laboratories | $949,266 | 0 |
| PERSIST-END Trial | Abbott Laboratories | $183,291 | 0 |
| Multi-Center Acute Safety Trial of TactiCath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) for the Treatment of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation | Abbott Laboratories | $128,002 | 0 |
| Safety and Effectiveness of TactiCath Contact Force Sensor Enabled (TactiCath SE) Catheter for Ablation of Drug Refractory Symptomatic Persistent Atrial Fibrillation (PERSIST-END Trial) | Abbott Laboratories | $7,281 | 0 |
Top Doctors Receiving Payments for TactiCath SE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Olympia, WA | $1.3M | 232 |
| , MD | Internal Medicine | Philadelphia, PA | $18,000 | 1 |
| , M.D | Cardiovascular Disease | Lexington, KY | $6,750 | 1 |
| , M.D | Clinical Cardiac Electrophysiology | Metairie, LA | $6,750 | 1 |
| , M.D | Internal Medicine | Pittsburgh, PA | $4,500 | 1 |
| , M.D | Cardiovascular Disease | Charlottesville, VA | $3,000 | 1 |
| , M.D | Cardiovascular Disease | Denver, CO | $3,000 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Cleveland, OH | $2,813 | 1 |
| , M.D | Internal Medicine | Milwaukee, WI | $2,250 | 1 |
| , M.D | Cardiovascular Disease | Milwaukee, WI | $2,250 | 1 |
| , D.O | Internal Medicine | Milwaukee, WI | $2,250 | 1 |
| , MD | Internal Medicine | Houston, TX | $1,688 | 1 |
| , M.D | Internal Medicine | Baltimore, MD | $1,515 | 1 |
| , DO | Cardiovascular Disease | Mountain View, CA | $900.00 | 2 |
| , M.D | Cardiovascular Disease | Minneapolis, MN | $764.00 | 1 |
| , MD | Vascular Neurology | Chicago, IL | $318.40 | 3 |
| , MD | Internal Medicine | Webster, TX | $106.13 | 1 |
| , M.D | Interventional Cardiology | Neptune, NJ | $106.12 | 1 |
| , M.D | Cardiovascular Disease | Baltimore, MD | $66.00 | 1 |
Ad
Manufacturing Companies
- Abbott Laboratories $1.3M
Product Information
- Type Device
- Total Payments $1.3M
- Total Doctors 18
- Transactions 253
About TactiCath SE
TactiCath SE is a device associated with $1.3M in payments to 18 healthcare providers, recorded across 253 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2018 to 2021. In 2021, $31,097 was paid across 9 transactions to 3 doctors.
The most common payment nature for TactiCath SE is "Unspecified" ($1.3M, 94.3% of total).
TactiCath SE is associated with 4 research studies, including "Safety and Effectiveness of TactiCath Contact Force, Sensor Enabled (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation (PERSIST-END Trial)" ($949,266).